Inhaled liposomal amikacin

References

• Mandell GL BJ, Dolin R. Principles and practice of infectious diseases. 6th edition. Elsevier Churchill Livingstone; Philadelphia, Pennsylvania, USA: 2010
   Google Scholar
• Gibson RL, Burns JL, Ramsey BW. Pathophysiology and management of pulmonary infections in cystic fibrosis. Am J Respir Crit Care Med 2003;168(8):918-51
   PubMed Web of Science ®Google Scholar
• Patient Data Registry Report [database on the Internet]. CF Foundation; Bethesda, MD, USA: 2011
   Google Scholar
• Waters V, Ratjen F. Multidrug-resistant organisms in cystic fibrosis: management and infection-control issues. Expert Rev Anti Infect Ther 2006;4(5):807-19
   PubMedGoogle Scholar
• Kosorok MR, Zeng L, West SE, et al. Acceleration of lung disease in children with cystic fibrosis after Pseudomonas aeruginosa acquisition. Pediatr Pulmonol 2001;32(4):277-87
   PubMed Web of Science ®Google Scholar
• Henry RL, Mellis CM, Petrovic L. Mucoid Pseudomonas aeruginosa is a marker of poor survival in cystic fibrosis. Pediatr Pulmonol 1992;12(3):158-61
   PubMed Web of Science ®Google Scholar
• Pamukcu A, Bush A, Buchdahl R. Effects of Pseudomonas aeruginosa colonization on lung function and anthropometric variables in children with cystic fibrosis. Pediatr Pulmonol 1995;19(1):10-15
   PubMedGoogle Scholar
• Cystic Fibrosis Canada. Canadian Patient Data Registry Report. Toronto, Canada: 2010
   Google Scholar
• Waters V, Yau Y, Prasad S, et al. Stenotrophomonas maltophilia in cystic fibrosis: serologic response and effect on lung disease. Am J Respir Crit Care Med 2011;183(5):635-40
   PubMed Web of Science ®Google Scholar
• Waters V, Atenafu EG, Lu A, et al. Chronic Stenotrophomonas maltophilia infection and mortality or lung transplantation in cystic fibrosis patients. J Cyst Fibros 2013;12(5):482-6
   PubMed Web of Science ®Google Scholar
• Corey M, Farewell V. Determinants of mortality from cystic fibrosis in Canada, 1970-1989. Am J Epidemiol 1996;143(10):1007-17
   PubMed Web of Science ®Google Scholar
• Tablan OC, Chorba TL, Schidlow DV, et al. Pseudomonas cepacia colonization in patients with cystic fibrosis: risk factors and clinical outcome. J Pediatr 1985;107(3):382-7
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Dorkin HL, Eisenberg JD, et al. Efficacy of aerosolized tobramycin in patients with cystic fibrosis. N Engl J Med 1993;328(24):1740-6
   PubMed Web of Science ®Google Scholar
• Ramsey BW, Pepe MS, Quan JM, et al. Intermittent administration of inhaled tobramycin in patients with cystic fibrosis. Cystic Fibrosis Inhaled Tobramycin Study Group. N Engl J Med 1999;340(1):23-30
   PubMed Web of Science ®Google Scholar
• Gibson RL, Emerson J, McNamara S, et al. Significant microbiological effect of inhaled tobramycin in young children with cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):841-9
   PubMed Web of Science ®Google Scholar
• MacLusky IB, Gold R, Corey M, Levison H. Long-term effects of inhaled tobramycin in patients with cystic fibrosis colonized with Pseudomonas aeruginosa. Pediatr Pulmonol 1989;7(1):42-8
   PubMedGoogle Scholar
• Steinkamp G, Tummler B, Gappa M, et al. Long-term tobramycin aerosol therapy in cystic fibrosis. Pediatr Pulmonol 1989;6(2):91-8
   PubMedGoogle Scholar
• Parkins MD, Elborn JS. Tobramycin Inhalation Powder: a novel drug delivery system for treating chronic Pseudomonas aeruginosa infection in cystic fibrosis. Expert Rev Respir Med 2011;5(5):609-22
   PubMed Web of Science ®Google Scholar
• Oermann CM, Retsch-Bogart GZ, Quittner AL, et al. An 18-month study of the safety and efficacy of repeated courses of inhaled aztreonam lysine in cystic fibrosis. Pediatr Pulmonol 2010;45(11):1121-34
   PubMed Web of Science ®Google Scholar
• Konstan MW, Flume PA, Kappler M, et al. Safety, efficacy and convenience of tobramycin inhalation powder in cystic fibrosis patients: the EAGER trial. J Cyst Fibros 2011;10(1):54-61
   PubMed Web of Science ®Google Scholar
• Schuster A, Haliburn C, Doring G, Goldman MH. Safety, efficacy and convenience of colistimethate sodium dry powder for inhalation (Colobreathe DPI) in patients with cystic fibrosis: a randomised study. Thorax 2013;68(4):344-50
   PubMed Web of Science ®Google Scholar
• Lagace J, Dubreuil M, Montplaisir S. Liposome-encapsulated antibiotics: preparation, drug release and antimicrobial activity against Pseudomonas aeruginosa. J Microencapsul 1991;8(1):53-61
   PubMed Web of Science ®Google Scholar
• Omri A, Beaulac C, Bouhajib M, et al. Pulmonary retention of free and liposome-encapsulated tobramycin after intratracheal administration in uninfected rats and rats infected with Pseudomonas aeruginosa. Antimicrob Agents Chemother 1994;38(5):1090-5
   PubMed Web of Science ®Google Scholar
• Beaulac C, Clement-Major S, Hawari J, Lagace J. Eradication of mucoid Pseudomonas aeruginosa with fluid liposome-encapsulated tobramycin in an animal model of chronic pulmonary infection. Antimicrob Agents Chemother 1996;40(3):665-9
   PubMed Web of Science ®Google Scholar
• Sachetelli S, Khalil H, Chen T, et al. Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells. Biochim Biophys Acta 2000;1463(2):254-66
   PubMed Web of Science ®Google Scholar
• Beaulac C, Sachetelli S, Lagace J. In-vitro bactericidal efficacy of sub-MIC concentrations of liposome-encapsulated antibiotic against gram-negative and gram-positive bacteria. J Antimicrob Chemother 1998;41(1):35-41
   PubMedGoogle Scholar
• Halwani M, Mugabe C, Azghani AO, et al. Bactericidal efficacy of liposomal aminoglycosides against Burkholderia cenocepacia. J Antimicrob Chemother 2007;60(4):760-9
   PubMed Web of Science ®Google Scholar
• Clancy J. Clinical Trials of Lipid-Associated Aerosolized Amikacin: the Arikace Story. Pediatr Pulmonol 2009;44:109-212
   Google Scholar
• Li Z, Zhang Y, Wurtz W, et al. Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size. J Aerosol Med Pulm Drug Deliv 2008;21(3):245-54
   PubMed Web of Science ®Google Scholar
• Konstan MW, Geller DE, Minic P, et al. Tobramycin inhalation powder for P. aeruginosa infection in cystic fibrosis: the EVOLVE trial. Pediatr Pulmonol 2011;46(3):230-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01315691
   Google Scholar
• Meers P, Neville M, Malinin V, et al. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections. J Antimicrob Chemother 2008;61(4):859-68
   PubMed Web of Science ®Google Scholar
• Prince AS. Biofilms, antimicrobial resistance, and airway infection. N Engl J Med 2002;347(14):1110-11
   PubMed Web of Science ®Google Scholar
• Chinoy MR, Fisher AB, Shuman H. Confocal imaging of time-dependent internalization and localization of NBD-PC in intact rat lungs. Am J Physiol 1994;266(6 Pt 1):L713-21
   Google Scholar
• ME Neville SL, Artis C, Dadey, E, Gupta, R. Functionality of foamy alveolar macrophages after inhalation of aerosolized liposomal amikacin (Arikace). Pediatr Pulmonol 2009;44:109-212
   Google Scholar
• Weers J, Metzheiser B, Taylor G, et al. A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers. J Aerosol Med Pulm Drug Deliv 2009;22(2):131-8
   PubMed Web of Science ®Google Scholar
• Okusanya OO, Bhavnani SM, Hammel J, et al. Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic Pseudomonal infection. Antimicrob Agents Chemother 2009;53(9):3847-54
   PubMed Web of Science ®Google Scholar
• Clancy JP, Dupont L, Konstan MW, et al. Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection. Thorax 2013;68(9):818-25
   PubMed Web of Science ®Google Scholar
• Bilton D, Pressler T, Isabelle F, et al. Phase 3 efficacy and safety data from randomized, multicenter study of liposomal amikacin for inhalation (Arikace) compared with TOBI in cystic fibrosis patients with chronic infection due to Pseudomonas aeruginosa. North American Cystic Fibrosis Conference; Salt Lake City, Utah. Pediatr Pulmonol 2013(Suppl 36):290
   Google Scholar
• Esther CR Jr, Henry MM, Molina PL, Leigh MW. Nontuberculous mycobacterial infection in young children with cystic fibrosis. Pediatr Pulmonol 2005;40(1):39-44
   PubMedGoogle Scholar
• Fauroux B, Delaisi B, Clement A, et al. Mycobacterial lung disease in cystic fibrosis: a prospective study. Pediatr Infect Dis J 1997;16(4):354-8
   PubMedGoogle Scholar
• Levy I, Grisaru-Soen G, Lerner-Geva L, et al. Multicenter cross-sectional study of nontuberculous mycobacterial infections among cystic fibrosis patients, Israel. Emerg Infect Dis 2008;14(3):378-84
   PubMed Web of Science ®Google Scholar
• Sermet-Gaudelus I, Le Bourgeois M, Pierre-Audigier C, et al. Mycobacterium abscessus and children with cystic fibrosis. Emerg Infect Dis 2003;9(12):1587-91
   PubMedGoogle Scholar
• Olivier KN, Weber DJ, Lee JH, et al. Nontuberculous mycobacteria. II: nested-cohort study of impact on cystic fibrosis lung disease. Am J Respir Crit Care Med 2003;167(6):835-40
   PubMed Web of Science ®Google Scholar
• Olivier KN, Weber DJ, Wallace RJ Jr, et al. Nontuberculous mycobacteria. I: multicenter prevalence study in cystic fibrosis. Am J Respir Crit Care Med 2003;167(6):828-34
   PubMed Web of Science ®Google Scholar
• Griffith DE, Aksamit T, Brown-Elliott BA, et al. An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases. Am J Respir Crit Care Med 2007;175(4):367-416
   PubMed Web of Science ®Google Scholar
• Aitken ML, Limaye A, Pottinger P, et al. Respiratory Outbreak of Mycobacterium abscessus Subspecies massiliense in a Lung Transplant and Cystic Fibrosis Center. Am J Respir Crit Care Med 2012;185(2):231-2
   PubMed Web of Science ®Google Scholar
• Gayathri R, Therese KL, Deepa P, et al. Antibiotic susceptibility pattern of rapidly growing mycobacteria. J Postgrad Med 2010;56(2):76-8
   PubMedGoogle Scholar
• Park S, Kim S, Park EM, et al. In vitro antimicrobial susceptibility of Mycobacterium abscessus in Korea. J Korean Med Sci 2008;23(1):49-52
   PubMedGoogle Scholar
• Yang SC, Hsueh PR, Lai HC, et al. High prevalence of antimicrobial resistance in rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2003;47(6):1958-62
   PubMedGoogle Scholar
• Shen GH, Wu BD, Wu KM, Chen JH. In Vitro activities of isepamicin, other aminoglycosides, and capreomycin against clinical isolates of rapidly growing mycobacteria in Taiwan. Antimicrob Agents Chemother 2007;51(5):1849-51
   PubMedGoogle Scholar
• Davis KK, Kao PN, Jacobs SS, Ruoss SJ. Aerosolized amikacin for treatment of pulmonary Mycobacterium avium infections: an observational case series. BMC Pulm Med 2007;7:2
   PubMedGoogle Scholar
• Colin AA. Eradication of Mycobacterium abscessus in a chronically infected patient with cystic fibrosis. Pediatr Pulmonol 2000;30(3):267-8
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Available from: http://clinicaltrials.gov/ct2/show/NCT01315236
   Google Scholar
• Chastre J, Fagon JY. Ventilator-associated pneumonia. Am J Respir Crit Care Med 2002;165(7):867-903
   PubMed Web of Science ®Google Scholar
• Niederman MS, Chastre J, Corkery K, et al. BAY41-6551 achieves bactericidal tracheal aspirate amikacin concentrations in mechanically ventilated patients with Gram-negative pneumonia. Intensive Care Med 2012;38(2):263-71
   PubMed Web of Science ®Google Scholar